Drug profile · INN
caplacizumab-yhdp
CABLIVI
caplacizumab-yhdp (CABLIVI) is a von willebrand factor inhibitor. Route of administration: injection. Current US regulatory status: approved.
Drug details — caplacizumab-yhdp
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
caplacizumab-yhdp (CABLIVI) is a von willebrand factor inhibitor. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
von Willebrand factor inhibitor
Primary target: von Willebrand factor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is caplacizumab-yhdp?
caplacizumab-yhdp (CABLIVI) is a von willebrand factor inhibitor. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for caplacizumab-yhdp?
CABLIVI is a marketed brand name for caplacizumab-yhdp. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of caplacizumab-yhdp?
caplacizumab-yhdp has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.